Discover
CORT
Corcept Therapeutics Incorporated
110.29
2 x 92.00
2 x 140.23
bid
ask
-
4.57
3.98%
2 @ 04:00 PM
111.00 +0.71 (0.64%)
| Ytd | 216.93% | |
| 1y | 38.21% |
108.41
day range
117.82
28.66
52 week range
126.38
| Open | 116.80 | Prev Close | 114.86 | Low | 108.41 | High | 117.82 | Mkt Cap | 11.92B |
| Vol | 17.23M | Avg Vol | 1.32M | EPS | 0.45 | P/E | 245.09 | Forward P/E | 25.05 |
| Beta | 0.45 | Short Ratio | 10.30 | Inst. Own | 76.90% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-04 | 50-d Avg | 108.16 | 200-d Avg | 68.40 | 1yr Est | 141.00 |
CORT News
benzinga.com
HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $165 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Corcept Therapeutics (NASDAQ:CO
businesswire.com
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercia
benzinga.com
Here’s How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 10 Years
Corcept Therapeutics (NASDAQ:CORT) has outperformed the market over the past 10 years by 20.4% on an
zacks.com
Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?
Corcept's Korlym sales rise 6.2% in H1 2026 as demand grows, while Lifyorli's launch offers a path t
fxempire.com
Corcept Grows to Mid-Cap on Institutional Support
Institutions keep buying Corcept Therapeutics Incorporated (CORT) shares in big volumes, sending the